The FDA has published the Guidance for Industry "Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification".
The scope of this
guideline applies to all trading partners such as manufacturers, repackers,
wholesalers and dispensers.
Since the 1st of January
2015, all trading partners of the FDA have to inform about any illegitimate
product identified as laid down in the Drug Supply Chain Security Act (DSCSA).
Now, the new guideline
lists specific scenarios and gives recommendations on how trading partners can
identify suspect products and inform the FDA about them. Moreover, the document
describes how to terminate a notification in line with the FDA.
If a company identifies a
suspect product, the FDA has to be informed within 24 hours.
Section A of the Guidance
depicts specific scenarios presenting the risk of suspected products if they
would enter the pharmaceutical supply chain. This includes:
1. Trading Partners and
Product Sourcing
2. Supply, Demand, History, and Value of the Product
3. Appearance of the Product
2. Supply, Demand, History, and Value of the Product
3. Appearance of the Product
Examples for the second
point include:
Products,
- that are generally in
high demand,
,- that have a high sales volume or a high price in the USA,
- that are offered at a price that is "too good to be true"
- that have been previously or are currently being counterfeited or diverted,
- that are currently the subject of a drug shortage
- that are the subject of an illegitimate product notification under the DSCSA,
- that are the subject of an FDA counterfeit or cargo theft alert.
,- that have a high sales volume or a high price in the USA,
- that are offered at a price that is "too good to be true"
- that have been previously or are currently being counterfeited or diverted,
- that are currently the subject of a drug shortage
- that are the subject of an illegitimate product notification under the DSCSA,
- that are the subject of an FDA counterfeit or cargo theft alert.
It is of fundamental
importance that all the trading partners have the necessary authorizations.
The FDA has a own webpage
for the notification of an illegitimate product. This page links to FDA Form 3911
which describes and sets the procedure to be followed.
Please click here to
access the complete document: Drug Supply Chain Security Act
Implementation: Identification of Suspect Product and Notification.
GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed.) Disclaimer: The Logos/Images & content posted here are belongs to respective to Authority / owners of firm. The Article posted under public health importance news.
0 comments:
Post a Comment